This information is intended for U.S. healthcare professionals and/or
healthcare professionals involved in healthcare reimbursement.
This site is intended for U.S. residents 18 years of age or older.
Live Support
1-800-861-0048
8 AM to 8 PM ET, Mon–Fri
We’d love your feedback on your experience today.
Please take this quick survey to help us continue to provide you with information
Supporting patient access
BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.
Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Read more about our coverage support offerings
Benefits Reviews
- Once a patient is enrolled in BMS Access Support, we can review their insurance coverage and provide a summary of benefits within approximately 24 hours*
- A benefits review may help determine whether or not a medication is covered, if a PA is required, and estimated patient out-of-pocket costs
*BMS Access Support Data - Benefits review. Accessed August 2022.
Prior Authorization (PA) and Appeals Assistance
- Use the BMS Access Map to identify plan-specific PA requirements
- View our forms and resources page for helpful support tools, including appeals letter templates and medical necessity letters
Annual Reverification
- Reverification of benefits is available upon request to confirm a patient’s benefits for the new year
- Connect with your local Access and Reimbursement Manager for more information
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Reimbursement and Coding Guide
for IDHIFA
Filter results by:
National Drug Codes (NDC)1
Issued by the FDA
Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
| 59572-0705-30 Copy | 50-mg tablets; one bottle containing 30 tablets |
| 59572-0710-30 Copy | 100-mg tablets; one bottle containing 30 tablets |
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)2
| C92 Copy | Myeloid Leukemia |
| C92.0 Copy | Acute myeloblastic leukemia |
| C92.00 Copy | Acute myeloblastic leukemia, not having achieved remission |
| C92.01 Copy | Acute myeloblastic leukemia, in remission |
| C92.02 Copy | Acute myeloblastic leukemia, in relapse |
Coding for IDHIFA is dependent on the insurer and the care setting in which the drug will be administered. Healthcare providers need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.
Please see U.S. Full Prescribing Information for IDHIFA, including Boxed WARNING.
*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient’s medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.
References:
- IDHIFA (enasidenib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm. Accessed August 3, 2023.
IDHIFA may be purchased through the distributors listed below.
Physician Offices
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Cardinal Health Specialty Pharmaceutical Distribution | 1-877-453-3972 | https://specialtyonline.cardinalhealth.com |
| CuraScript Specialty Distribution | 1-877-599-7748 | https://www.curascriptsd.com |
| McKesson Specialty Health | 1-800-482-6700 | https://mscs.mckesson.com |
| Morris & Dickson Specialty | 1-800-710-6100 | Fax: 1-318-524-3096 https://www.mdspecialtydist.com |
| Oncology Supply | 1-800-633-7555 | https://www.oncologysupply.com |
For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain IDHIFA from the distributors listed above.
Hospitals and Infusion Centers
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| ASD Healthcare | 1-800-746-6273 | Fax: 1-800-547-9413 https://www.asdhealthcare.com |
| Cardinal Health Specialty Pharmaceutical Distribution | 1-866-677-4844 | Fax: 1-614-553-6301 https://orderexpress.cardinalhealth.com |
| McKesson Plasma and Biologics | 1-877-625-2566 | Fax: 1-888-752-7626 https://connect.mckesson.com |
| Morris & Dickson Specialty | 1-800-710-6100 | Fax: 1-318-524-3096 https://www.mdspecialtydist.com |
Puerto Rico Hospitals and Clinics
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Amerisource Bergen Puerto Rico |
1-844-222-2273 | https://abcorder.amerisourcebergen.com |
| Cardinal Puerto Rico (Borschow) | 1-787-625-4200 | https://www.cardinalhealth.pr |
| Cesar Castillo, Inc. | 1-787-641-5242 (Hospitals) 1-787-641-5082 (Specialty Pharmacy) |
Fax: 1-787-999-1614 https://www.facilfarmaciacci.com |
Above information is accurate as of 12/23.
The IDHIFA distribution program includes extended payment terms to Bristol Myers Squibb authorized IDHIFA distributors. Healthcare providers and institutions should contact their IDHIFA distributor to understand specific payment terms that may be available to them from their distributor.
Please see U.S. Full Prescribing Information for IDHIFA, including Boxed WARNING.
FDA Approval Letter as Posted by the FDA:
For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test
View LetterPlease see U.S. Full Prescribing Information for IDHIFA, including Boxed WARNING.
